Editas Medicine, Inc. Common Stock
EDITEditas Medicine, Inc. (EDIT) is a biotechnology company focused on developing gene editing therapies using CRISPR technology. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company aims to treat genetic disorders by precisely editing DNA to correct mutations. It develops in vivo and ex vivo gene editing treatments targeting ophthalmic, hematologic, and other genetic diseases.
Company News
The global gene therapies for cancer treatment market is expected to grow from $8.28 billion in 2024 to $238.77 billion by 2034, with a 39.94% CAGR. North America currently dominates the market, with CAR-T cell therapy leading market share and significant innovations driving growth.
Healthcare companies are advancing precision medicine through gene therapy, AI diagnostics, and innovative treatments targeting age-related conditions, with several firms making significant breakthroughs in areas like longevity biotechnology and personalized care.
Two biotech companies, Editas Medicine and Sarepta Therapeutics, are experiencing severe challenges that make them unattractive investment options. Editas Medicine lacks marketable products and has a history of abandoned projects, while Sarepta Therapeutics is dealing with patient deaths related to its gene therapy treatment Elevidys.
Editas (EDIT) reports positive new safety and efficacy data from the RUBY and EdiTHAL studies evaluating its investigational gene therapy, reni-cel, for SCD and TDT, respectively.
